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Abstract. Anti-cancer drugs typically exert their pharmacological effect on tumors by inducing apoptosis, or
programmed cell death, within the cancer cells. However, no tools exist in the clinic for detecting apoptosis in
real time. Microscopic examination of surgical biopsies and secondary responses, such as morphological changes,
are used to verify efficacy of a treatment. Here, we developed a novel near-infrared dye-based imaging probe to
directly detect apoptosis with high specificity in cancer cells by utilizing a noninvasive photoacoustic imaging
(PAI) technique. Nude mice bearing head and neck tumors received cisplatin chemotherapy (10 mg/kg) and were
imaged by PAI after tail vein injection of the contrast agent. In vivo PAI indicated a strong apoptotic response to
chemotherapy on the peripheral margins of tumors, whereas untreated controls showed no contrast enhancement
by PAI. The apoptotic status of the mouse tumor tissue was verified by immunohistochemical techniques staining
for cleaved caspase-3 p11 subunit. The results demonstrated the potential of this imaging probe to guide the
evaluation of chemotherapy treatment. C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3650240]
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1 Introduction
Noninvasive imaging techniques are necessary for early cancer
detection and evaluation of the chemotherapeutic effect on tu-
mors. Current diagnostic imaging techniques generally include
γ -scintigraphy, magnetic resonance imaging, computed tomog-
raphy, and ultrasonography; however, these techniques only give
morphological information on the tumor. These techniques do
not report the biochemical response of the tumor to treatment and
physical changes in the tumor in response to treatment may take
days to weeks to fully manifest. Positron emission topography
and SPECT can indirectly detect tumor response to treatment
due to changes in metabolic activity and blood perfusion, re-
spectively. However, no clinical imaging technique can directly
detect the biochemical response, e.g., apoptosis, of tumors to
treatment. Since apoptosis often occurs within in the first 18 to
36 h after treatment, direct imaging of apoptosis would rapidly
indicate if there is a response in the tumor to chemotherapy.
Photoacoustic imaging (PAI) overcomes the spatial and res-
olution limitations of conventional imaging techniques at a rel-
atively low cost,1, 2 and it has shown its potential to monitor the
growth of melanoma brain tumors3 and melanoma metastasis
in sentinel lymph nodes.4 However, ascribed to the fact that
PAI utilizes the optical absorption of tissues for contrast, it can-
not differentiate normal from cancerous cells unless the cells
are overexpressing chromomeric marker (e.g., melanomas) or
labeled by reporter moieties as contrast agent to enhance the
contrast between normal and pathological tissues. In this case,
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application of a contrast agent such as fluorochromes is expected
to facilitate both the visualization of head and neck squamous
cell carcinoma (HNSCC) cancer cells and their response to treat-
ment in vivo by PAI.
We have synthesized a near-infrared fluorescent imaging
probe – IR780-linker-Val-Ala-Glu(OMe)-FMK by conjugating
a fluorochrome (IR780) to Z-Val-Ala-Glu (OMe), a cell
permeable caspase inhibitor. The activation of caspase family
of cysteine proteases has been recognized as a critical event
of apoptosis, which is a physiological process of type I pro-
grammed cell death. Typically anti-cancer agents act on cancer
cells to induce apoptosis, so apoptosis is a rapid and definite
indicator of tumor response. For this reason, apoptosis is used
in screening drug candidates in cell culture. The fluoromethyl
ketone of the tripeptides valine, alanine, and O-methyle-
glutamic acid [Val-Ala-Glu(OMe)-FMK] can specifically and
irreversibly bind to the cysteine residue at the active site of
caspase-9.5 Our preliminary in vitro cell-imaging test with
prostate cancer DU 145 cells demonstrated the sensitivity of this
imaging probe for cell apoptosis.6 In this study, we evaluated
the application of IR780-linker-Val-Ala-Glu(OMe)-FMK for
PAI to detect procaspase-9 activation caused by anticancer drug
treatment in living nude mice bearing HNSCC tumors.
2 Materials and Methods
2.1 Photoacoustic Imaging System
The mechanism of the PAI system was previously described2, 3
and is identical to the system presented by Song et al.1 A
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tunable OPO laser (Surelite OPO PLUS; Continuum, Santa
Clara, California) pumped by a Q-switched Nd:YAG laser (Sure-
lite; Continuum, Santa Clara, California) is used to generate the
laser pulse with a repetition rate of 10 Hz and a laser wavelength
of 680 nm. The laser light, directed by a prism group, forms a
ring-shaped illumination on an optical condenser and is then
refocused by a conical lens on the targeted area. The produced
photoacoustic signals are collected by a 5-MHz single-element
focused ultrasonic transducer (SU-108-013, Sonic Concepts,
Bothell, Washington), amplified by a pre-amplifier (5072PR,
Olympus-NDT, Waltham, Massachusetts), and finally collected
by a personal computer through an A/D Scope Card (CS21G8-
256MS, Gage, Lockport, Illinois) with a 125-MHz sampling
rate to reconstruct 2-D images. The 5-MHz ultrasonic trans-
ducer (fractional bandwidth of 60%, 35-mm focal length, and
33-mm aperture size) is mounted in the center of the condenser
and driven by a step motor to scan over the targeted region.
It takes ca. 20 min to scan a 20 mm × 20 mm area. Previous
work2, 3 on this system has shown that it has a lateral resolution
of 270 μm and an axial resolution of 220 μm.
2.2 Imaging Agent
The near-infrared fluorescent imaging agent – IR780-linker-
Val-Ala-Glu(OMe)-FMK (NIR-FMK) was synthesized in our
laboratory.6 The imaging agent had a maximum absorption
wavelength at 640 nm and emission wavelength at 729 nm
with a quantum yield of 0.75. Sensitivity of this imaging agent
for cell apoptosis imaging was tested by in vitro cell imaging.
Cellular uptake of NIR-FMK was compared between normal
prostate cancer DU-145 cells and anticancer treated DU-145
cells. The results demonstrated that cancer cells undergoing
apoptosis presented a significant signal when they were fluo-
rescently imaged, resulting from uptake of the imaging agent;
while normal cancer cells showed the concentration dependent
uptake of it. (Qualification of this dye for fluorescent imaging is
described elsewhere.6)
2.3 Tumor Model
Female Nu/Nu mice used in the experiments were maintained
under the supervision and guidelines of the University of Kansas
Institutional Animal Care and Use Committee. Animals were fed
on a diet of low chlorophyll feed for at least two weeks before
imaging. Human HNSCC cells, MDA-1986, were prepared in
1×PBS solution at a cell concentration of 2 × 107 cells/mL.
Nude mice were anesthetized with 1.5% isoflurane in oxygen-
air mixture (50:50). Fifty microliters of cell suspension was
injected into the sub-mucosa of a mouse using a 30-ga needle.
Primary HNSCC tumors were observed on the cheek of the
animals two weeks after implantation with a size range of 5
to 150 mm3 [tumor volume = 0.52 × (width)2 × (length)].
Animals were euthanized at the completion of the study.
2.4 Treatment and Fluorescent Imaging
Female nude mice bearing head and neck tumors were randomly
divided into two groups, including cisplatin treatment and con-
trol groups. One dose of 10.0-mg/kg cisplatin (LC Laboratories)
was intravenously administered via the tail vein to the animals
in the treatment group once the tumor size was between 40 to
Fig. 1 Fluorescent images of systemic clearance of NIR-FMK constrast
agent. Animal was fluorescently imaged after tail vein injection of
25 nmol of NIR-FMK. Agent rapidly cleared from the systemic circu-
lation and was concentrated in the liver from 5 to 30 min and in the
intestines from 1 to 6 h. The structure of NIR-FMK is shown in the
bottom panel.
50 mm3. The control group received no treatment. NIR-FMK (25
nmol in 100-μL of saline) was intravenously injected via the tail
vein into a tumor-negative mouse, and systemic clearance of the
dye was evaluated by fluorescent imaging (CRI Maestro Flex,
CRI Inc., Woburn, Massachusetts) throughout 5 min to 24 h. A
575 to 605-nm filtered halogen excitation light and a 645-nm
long pass emission filter were applied. Fluorescence intensity
in the abdominal area was measured using a cooled charge-
coupled-device (CCD) camera with auto exposure (Fig. 1).
The unscaled images were normalized to the same exposure
and the brightness and constrast were adjusted for print.
2.5 In Vivo Photoacoustic Imaging
Twenty-four hours post-treatment with cisplatin, mice were po-
sitioned as shown in Fig. 2 (top) and anesthetized by inhalation
of a mixture of 1% isoflurane and pure oxygen at 1-L/min flow
rate. The initial background photoacoustic (PA) images were
obtained around the tumor region on the cheek of the mouse and
then NIR-FMK (25 nmol in 100 μL of saline) was intravenously
injected via the tail vein. PA images were acquired at 2, 4, 6,
and 8 h. A laser wavelength of 680 nm was used during the
imaging, and the imaging depth was 2 to 3 mm. Signal inten-
sity was analyzed using Fiji/ImageJA software (ver. 20110307,
http://pacific.mpi-cbg.de/wiki/index.php/Fiji).
2.6 Immunostaining for Apoptosis
The HNSCC tumor was excised within several hours af-
ter PAI. Subsequently, it was embedded into tissue freezing
medium (Triangle Biomedical Sciences, Durham, North Car-
olina) and sectioned using a cryostat (Thermo Shandon Limited,
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Fig. 2 Increase in PA amplitude within the HNSCC tumor after intra-
venous injection of imaging agent via the tail vein. The treated animals
(n = 2) were intravenously given 10 mg/kg of cisplatin 24 h prior to
administration of the imaging agent. PAI images were centered on the
tumor (circle, bottom). Images of the control animal (n = 1) at the
optimal imaging depth were chosen for data analysis.
Kalamazoo, Michigan). Fourteen micron (thickness) sections of
the tumor tissue were stained with a goat primary polyclonal
antibody for cleaved caspase-3 p11 subunit (Asp-175-Ser-176)
and a donkey anti-goat secondary antibody with a fluorescein
isothiocyanate (FITC) fluorophore (Santa Cruz Biotechnology
Inc., Santa Cruz, California). Cell nuclei were stained with 4′,6-
diamidino-2-phenylindole (DAPI).
3 Results and Discussion
Systemic clearance of the imaging agent from a tumor-free
mouse was evaluated by injecting animals with 25 nmol of
NIR-FMK via their tail vein and fluorescently imaging animals
from 5 min to 24 h. Fluorescence signals in the abdominal
area shown in Fig. 1 indicated that NIR-FMK was retained by
the liver within the first 5 min after injection, with later distri-
bution to the small intestines and spleen. Organ fluorescence
decreased to background or autofluorescence levels after eight
hours, indicating that the agent had been completely cleared
from the body. The kinetics of clearance of NIR-FMK served
to assist with determining the time course of PA imaging on
tumor-positive mice. Within the first hour, the liver had cleared
the imaging agent from the systemic circulation, offering a fa-
vorable time frame for PA imaging to differentiate the imaging
agents bound to the tumor tissue from the free agent distributed
in the tissue space. In addition, considering the imaging reso-
lution and patients’ comfort in future clinical applications, we
performed the PA imaging at 2, 4, 6, and 8 h after intravenous
injection.
Maximum amplitude projection images obtained from the
PAI of the HNSCC tumor region shown in Fig. 2 were con-
verted to grayscale images. The grayscale images at various time
points were linearly aligned using the scale-invariant feature
transform function of Fiji/ImageJA software (ver. 20110307,
http://pacific.mpi-cbg.de/wiki/index.php/Fiji) (Fig. 3). Quantifi-
cation of PA signal intensity within the tumor region was per-
formed in triplet for each image by measuring the mean gray
value (units: gray/pixel) of the circled tumor region. The extent
of signal enhancement was calculated by normalizing the tumor
signal against a background reading taken immediately before
injection of the imaging agent (Fig. 2), and the process can be
indicated with the following equation:
Increase in PA signal = [(intensity of each time point
− intensity of background image)/
intensity of background imaging]
× 100%.
Fig. 3 PA images of HNSCC tumor apoptosis after contrast treatment. Animals were administered 25 nmol of NIR-FMK via the tail vein. Intravenous
cisplatin (10 mg/kg) was administered 24 h prior to imaging in the treatment group.
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Fig. 4 Immunostaining for apoptosis in tumor. (a) Representative con-
trol section stained with secondary antibody alone and (b) tissue section
of the HNSCC tumor stained for caspase-3 p11 subunit after cisplatin
treatment. Green FITC fluorescence indicates the presence of apoptotic
cells and blue DAPI indicates the cell nuclei.
The signal intensity within the tumor region of each frame
(denoted by a white circle in Fig. 3) was compared with other
frames in the same time series between the treated and control
groups. The same scaling was used for all images within the
series. The triangle-shaped white region in the lower left corner
of the control group images in Fig. 3 is noise from a piece of
paper used to cover the right eye, which is outside of the HNSCC
tumor region.
The signal of the mouse in the control group reached the
maximum intensity at 2 h and after that it began to drop. This
indicated that the imaging probe was nonspecifically distributed
to the tumor tissues after injection, and the agent then cleared
with the systemic circulation as observed in the fluorescence
studies (Fig. 1). By comparison, PA images of the treatment
group demonstrated enhanced signal intensity during the same
time course. The significant difference between control and
cisplatin treatment groups could be explained by the specific
and irreversible binding between NIR-FMK and caspase
9 in the tumor tissue. In cisplatin treated mice, apoptosis of
HNSCC cancer cells resulted in the activation of caspase
9 around the tumor, serving as binding sites for the imaging
probe and allowing the probe to accumulate.7 Since the control
group did not receive the chemotherapy treatment, caspase
9 was not activated due to the lack of the cell apoptosis process
and the imaging probe was rapidly cleared from the tumor.
Diffuse contrast on the peripheral of the tumor region in the
treated group is likely due to apoptosis of metastatic cells on
the margins of the solid primary tumor mass.
Apoptosis in the tumor tissues was independently verified
by immunohistochemical staining for caspase 3, a downstream
indicator of apoptosome-activated caspase-mediated apopto-
sis that would not cross-react with the caspase-9 PA probe.
Figure 4(a) represents a control section stained with the sec-
ondary antibody alone (autofluorescence of the tissue without
apparent staining); while, Fig. 4(b) shows the immunostaining
of the caspase-3 p11 subunit (green) and the DAPI staining of
cell nuclei. The intense green fluorescence in these sections sug-
gests the wide spread apoptosis of cells in the tumor tissues after
intravenous administration of high-dose cisplatin. In addition,
cells on the peripheral of the tumor stained more strongly for
caspase 3 (green fluorescence) compared to cells at the tumor
interior. This was consistent with the PA imaging of apoptosis
that showed strong apoptosis at the tumor peripheral, suggesting
chemotherapeutics had penetrated the outer layers of the tumor
and induced apoptosis.
In conclusion, we developed a cell-permeable imaging probe
that can be utilized to monitor cancer cell apoptosis in living
mice by photoacoustic imaging with improved contrast.
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